Short answer
GYRE THERAPEUTICS, INC. (GYRE) filed its Q1 2026 10-Q quarterly report on May 8, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $23M (up 2.1% year over year) with net income of −$10M.
Q1 2026 key financials · XBRL
- Revenue
- $23M
- +2.1% YoY
- Net income
- −$10M
- −364.0% YoY
- Operating margin
- -41.5%
- EPS (diluted)
- −$0.10
Source: XBRL data from the GYRE THERAPEUTICS, INC. (GYRE) Q1 2026 10-Q on SEC EDGAR. USD.
GYRE THERAPEUTICS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $22.5M, up 2% YoY from $22.1M, led by Contiva and Etorel sales increases of $0.5M and $0.7M
- Net loss $9.9M vs net income $3.7M YoY; operating loss $9.4M vs income $2.3M
- Best performer Etorel, sales up $0.7M; weakest ETUARY, revenue down approximately 3% YoY
- Cash and equivalents $37.5M vs $37.1M at December 31, 2025; operating cash flow $3.2M
- Near-term headwinds: additional Cullgen transaction costs expected; research and development investments expected to continue near to medium term
Risk Factors
- No material changes from Annual Report risk factors
- Merger agreement with Cullgen dated March 2, 2026, creating transaction-execution exposure
- No new regulatory, legal, compliance, operational, competitive, market, or financial risks disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GYRE THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.